Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses

Maze Therapeutics

11/08/2026 21:12

Overview
US biopharma's Q2 net loss widened and missed analyst expectations
Q2 income from operations missed analyst estimates
Company ended Q2 with $495 mln in cash after $150 mln equity raise

Outlook
Maze expects HORIZON trial data for MZE829 in late 2026 or early 2027
Topline data from CIPheR trial of MZE782 in PKU expected in 2027
Company expects cash runway to fund operations into 2029

Result Drivers
R&D SPENDING - Co said higher R&D expenses were mainly due to progression of MZE829 clinical development and increased personnel-related costs
ADMINISTRATIVE COSTS - Co said higher G&A expenses were mainly due to increased personnel-related expenses and professional service costs

Company press release: ID:nGNX3X3kmd

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$44.73 mln
$42.42 mln (10 Analysts)
Q2 Income from Operations
Miss
-$48.04 mln
-$45.24 mln (10 Analysts)
Q2 Operating Expenses
 
$48.04 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Maze Therapeutics, Inc. is $55.50, about 103.4% above its August 10 closing price of $27.28

Reuters Recommended Reads
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Bristol Myers to build $2.3 billion manufacturing site in Houston

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)